Sublocade vs Brixadi
both long-acting buprenorphine injections reviewed for opioid use disorder
Sublocade(Buprenorphine)
Indivior PLC · 226 cited findings →
Brixadi(buprenorphine extended-release)
Braeburn · 211 cited findings →
What the regulatory reviews say
Sublocade and Brixadi are long-acting buprenorphine injections reviewed for opioid use disorder (OUD). Sublocade is indicated for the treatment of moderate to severe OUD in patients who have undergone induction to suppress opioid withdrawal signs and symptoms with a transmucosal buprenorphine-containing product. Brixadi is indicated for the treatment of moderate to severe OUD.
Sublocade's review noted a treatment success rate (responder) of 28%-29%, with a 2% difference compared to placebo. The cumulative percentage of negative opioid use (100%) for placebo was 1%. Brixadi's review reported a responder rate of 16.9% for CAM2038 and 13.9% for SL BPN/NX, with a responder rate difference of 2.9% between CAM2038 and SL BPN/NX.
It is crucial to note that these drugs were studied in separate trials with different designs, populations, and timepoints. The endpoints, patient populations, and comparator arms varied between the studies. Therefore, the figures presented are not head-to-head comparisons, and neither drug is presented as superior to the other.
Each drug's own results — cited
| Sublocade | Brixadi | |
|---|---|---|
| Treatment success/Responder rate | 28 %-29 % Treatment success rate (responder) Sublocade FDA Review, p.12 | 16.9% Responder rate (CAM2038) Brixadi FDA Review, p.10 |
| Responder rate vs comparator | 2% Treatment success rate (responder) vs placebo Sublocade FDA Review, p.12 | 2.9% Responder rate difference (CAM2038 vs SL BPN/NX) Brixadi FDA Review, p.10 |
| Percentage of negative drug use | 12-13% Percentage of patients with 100% negative drug use Sublocade FDA Review, p.12 | 35.1 Mean percentage of urine samples negative for illicit opioids (CAM2038, Weeks 5-25) Brixadi FDA Review, p.12 |
Explore the full evidence
Every cited finding behind both drugs is in the Psychiatry research library →
Figures are as stated in the cited regulatory review documents. Educational reference only — not medical or investment advice.